Originally published by our sister publication Gastroenterology & Endoscopy News
By Jillian Mock
SAN DIEGO—The results of several studies presented at The Liver Meeting 2024 suggest there is a robust treatment pipeline for metabolic dysfunction–associated steatohepatitis and metabolic dysfunction–associated steatotic liver disease.
“These are exciting times in the field of MASLD/MASH, with a very promising pipeline of pharmacotherapies in development,” said Bubu